The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

In the tumor microenvironment, T cells, B cells, and many other cells play important and
distinct roles in anti‐tumor immunotherapy. Although the immune checkpoint blockade and …

INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …

Autoimmunity is intrinsically driven by memory T and B cell clones inappropriately targeted
at self-antigens. Selective depletion or suppression of self-reactive T cells remains a holy …

Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have
improved survival in patients with solid and haematologic malignancies,,,,,,,–. Adults with T …

Mutations in the RAS oncogenes occur in multiple cancers, and ways to target these
mutations has been the subject of intense research for decades. Most of these efforts are …

In the field of oncology, clinical investigations of immune checkpoint inhibitors now
predominate. These drugs, delivered as antibody therapies that activate T-lymphocyte …

Receptor clustering is the most critical step to activate extrinsic apoptosis by death receptors
belonging to the TNF superfamily. Although clinically unsuccessful, using agonist …

The success of chimeric antigen receptor (CAR) T cells in treating B cell malignancies
comes at the price of eradicating normal B cells. Even though T cell malignancies are …

Target identification for chimeric antigen receptor (CAR) T-cell therapies remains
challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular …